What do federal funding cuts mean for MS researchers and those living with the disease? Then, should you kiss your dentist ...

The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in ...

—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. Share on ...

The first signs of multiple sclerosis (MS) may appear much earlier than most doctors once believed. A new study suggests that ...

After her own multiple sclerosis diagnosis 10 years ago, Parisa Khosravi became an advocate and a clinician for an autoimmune ...

—Investigators conducted an analysis using self-reported data from European multiple sclerosis patients to assess the prevalence of bladder problems and their impact on well-being. Share on Facebook.

Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a ...

Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

Neurodegeneration in multiple sclerosis can be monitored via OCT of inner retinal layers in the macular region, according to ...

To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently ...

Read more in the PNW Health series. For decades, when someone in Washington state had to manage multiple sclerosis, care quality often depended on where that person lived. Rural Washingtonians ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...